---
title: "GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths"
description: "About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds."
publisher: "The Inference"
section: "Health"
published: 2026-11-19T18:12:46.677Z
modified: 2026-11-19T18:12:46.677Z
canonical: https://theinference.org/article/ge-healthcare-s-manganese-mri-agent-matched-gadolinium-in-phase-2-a-route-past-china-s-rare-earth-chokepoint
language: en
keywords: "GE HealthCare, Rare Earths, Contrast Agents, Medical Devices, China Export Controls"
---

# GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

> About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

[GE HealthCare](https://theinference.org/markets/companies/ge-healthcare) said on November 19 that mangaciclanol, its investigational manganese-based MRI contrast agent, [met the primary endpoint of the LUMINA trial's Phase 2 stage](https://finance.yahoo.com/healthcare/articles/ge-healthcare-phase-2-results-130000484.html): blinded independent readers found overall diagnostic preference similar between it and gadobutrol, the market-leading gadolinium agent [1]. It was well tolerated, with no safety concerns identified, and the Phase 3 dose is set at 0.1 mmol/kg [1]. The first patient was dosed at Mayo Clinic in April 2026, and the candidate carries the US Food and Drug Administration's Fast Track designation [1].

## Sixty-five million scans a year ride on one rare earth

Around 65 million contrast-enhanced MRI procedures a year run on gadolinium agents, roughly a third of all MRI scans [1]. GE HealthCare calls the rare earth largely dependent on Chinese mining and processing [1], and Beijing's April 2025 [export licensing of seven medium and heavy rare earths](https://www.msn.com/en-us/money/general/china-rare-earth-export-controls-pause-ends-tuesday-in-law-beijing-has-published-no-extension/ar-AA2h3M5N), gadolinium among them, has stayed in force through every truce since [2]. Manganese, an essential element the body already regulates, is available from multiple countries [1].

*Chart: **China's grip tightens to 97 percent down the rare-earth chain** Bar chart of China's estimated share of global rare-earth output: about 70 percent at mining, about 90 percent at refining and processing, and 97 percent at heavy rare-earth oxide separation.*

*Estimated shares of global rare-earth output at each stage; gadolinium is a heavy rare earth. Sources: Tech Times relaying Motley Fool research and BISI estimates, November 2026. [2]*

## The hedge guards a 29.9 percent margin

[Pharmaceutical Diagnostics](https://theinference.org/article/ge-healthcare-beat-and-raised-then-filed-the-exit-of-the-pcs-chief-to-a-rival-s-top-job), the unit that sells contrast agents, booked $846 million of [third-quarter revenue](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000059/gehc-20260930.htm), up 13.0 percent, or $97 million, as reported [3]. Its segment EBIT margin, operating profit as a share of revenue, came to 29.9 percent, against 15.3 percent for the imaging segment, the highest of the company's three segments [3].

*Chart: **The contrast-agent unit earns twice the imaging unit's operating margin** Column chart of third-quarter 2026 operating margins: Pharmaceutical Diagnostics 29.9 percent, Imaging 15.3 percent, and GE HealthCare total company 14.6 percent.*

*Operating profit as a share of revenue, third quarter ended 30 September 2026. Segment figures are segment EBIT; the company figure is total operating margin, which carries corporate costs the segments do not. Sources: GE HealthCare Form 10-Q, 28 October 2026, and quarterly figures from its SEC filings. [3][7]*

The unit supports 140 million patient procedures a year [1], added a $138 million plant expansion in Cork, Ireland [1], and agreed in October to pay [$945 million for SOFIE Biosciences](https://theinference.org/article/ge-healthcare-pays-945-million-for-sofie-biosciences-15-plant-pet-isotope-network), a 15-plant PET isotope network, with the antitrust review running toward a first-half 2027 close [4]. Mangaciclanol's case is supply security for a segment that already runs on gadolinium agents, not new chemistry.

## Parity is a low bar, and manganese has lost before

The release carries no price, no approval date and no Phase 3 budget, and its endpoint was similarity, not superiority [1]. The data stay company-reported until December 1, when the images screen at the RSNA radiology congress in Chicago [1]. Manganese has lost here before: Teslascan, an earlier agent for liver MRI, was withdrawn from the US market in 2003 and from Europe in 2012 for commercial reasons [5].

The incumbent is dug in: Bayer's Gadavist, [the gadobutrol brand](https://www.radiologysolutions.bayer.com/mr/mr-contrast-agents/gadavist-injection), has sold more than 44 million US vials since 2011 at the same 0.1 mmol/kg dose, in a cage rated at more than 1,000 years before it lets gadolinium go [6]. GEHC shares slipped 1.14 percent on the day [1].

## December 1 puts the images on the record

Watch December 1 at RSNA, when outside readers see the images the blinded readers saw [1]. The open question is whether those readers stay indifferent in Phase 3, which widens the test from the brain and spine to the rest of the body [1].

## Takeaway

Mangaciclanol matched Bayer's gadobutrol on blinded reads in Phase 2, giving GE HealthCare a hedge for a Pharmaceutical Diagnostics unit that earns a 29.9 percent margin, more than twice the company's operating margin, and runs on a rare earth China licenses.

## Sources

1. [Business Wire via Yahoo Finance, "GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial", 19 November 2026](https://finance.yahoo.com/healthcare/articles/ge-healthcare-phase-2-results-130000484.html)
2. [Tech Times via MSN, "China rare earth export controls pause ends Tuesday in law; Beijing has published no extension", 9 November 2026](https://www.msn.com/en-us/money/general/china-rare-earth-export-controls-pause-ends-tuesday-in-law-beijing-has-published-no-extension/ar-AA2h3M5N)
3. [GE HealthCare Technologies Inc., Form 10-Q for the quarter ended 30 September 2026, filed with the SEC 28 October 2026](https://www.sec.gov/Archives/edgar/data/1932393/000193239326000059/gehc-20260930.htm)
4. [The Inference, "GE HealthCare pays $945 million for SOFIE Biosciences' 15-plant PET isotope network", 16 October 2026](https://theinference.org/article/ge-healthcare-pays-945-million-for-sofie-biosciences-15-plant-pet-isotope-network)
5. [Wikipedia, "Mangafodipir", retrieved 19 November 2026](https://en.wikipedia.org/wiki/Mangafodipir)
6. [Bayer in Radiology, "Gadavist (gadobutrol) injection", product page, last updated September 2026](https://www.radiologysolutions.bayer.com/mr/mr-contrast-agents/gadavist-injection)
7. [GE HealthCare, quarterly figures from its SEC filings, retrieved 19 November 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001932393)


---

GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths — The Inference. Canonical: https://theinference.org/article/ge-healthcare-s-manganese-mri-agent-matched-gadolinium-in-phase-2-a-route-past-china-s-rare-earth-chokepoint
